Patents Assigned to Nektar Therapeutics
  • N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides
    Patent number: 9907855
    Abstract: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: March 6, 2018
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang
  • Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
    Patent number: 9908970
    Abstract: Provided herein are polymeric ?-hydroxy aldehyde or ?-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. The substituent is appropriately situated, via a linker if necessary, to position the group for proton abstraction, preferably providing a 4- or 5-bond spacing between the abstracting atom and the hydrogen atom on the ?-carbon. Also provided are methods of using the reagents and stable, solubilized conjugates of the reagents with biologically active compounds. In preferred embodiments, the polymeric component of the reagent or conjugate is a polyethylene glycol.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: March 6, 2018
    Assignee: Nektar Therapeutics
    Inventors: Sean M. Culbertson, Xiaoming Shen, Antoni Kozlowski, Samuel P. McManus
  • Conjugates of an IL-2 moiety and a polymer
    Patent number: 9861705
    Abstract: Conjugates of an interleukin-2 (“IL-2”) moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: January 9, 2018
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Cherie F. Ali, Xiaofeng Liu, Deborah H. Charych, Yujun Wang
  • Polymer-active agent conjugate
    Patent number: 9839695
    Abstract: The invention provides for preparing a polymer-active agent conjugate, the method comprising the steps of reacting an amino acid derivative with a biologically active agent under conditions to form a polymer-active agent conjugate.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: December 12, 2017
    Assignee: Nektar Therapeutics
    Inventor: Antoni Kozlowski
  • Polymer-sunitinib conjugates
    Patent number: 9827326
    Abstract: The invention relates to (among other things) polymer-sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over sunitinib in unconjugated form.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: November 28, 2017
    Assignee: Nektar Therapeutics
    Inventors: Sean M. Culbertson, Antoni Kozlowski, Tony Drew Vinson
  • N-maleimidyl polymer derivatives
    Patent number: 9828465
    Abstract: The invention is directed to multi-functional N-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a N-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless N-maleimidyl polymer derivatives.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: November 28, 2017
    Assignee: Nektar Therapeutics
    Inventor: Xiaoming Shen
  • Oligomer-opioid agonist conjugates
    Patent number: 9827239
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water—soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water—soluble oligomer.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: November 28, 2017
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Kappa opioid agonists and uses thereof
    Patent number: 9815824
    Abstract: Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. The present disclosure relates to novel compounds and to their use as agonists of the kappa opioid receptor. The disclosure also relates to methods for preparation of the compounds and to pharmaceutical compositions containing such compounds. Kappa opioid agonists that exhibit full agonist properties at the kappa opioid receptor have been widely shown to be efficacious in preclinical models of pain, particularly visceral pain.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: November 14, 2017
    Assignee: Nektar Therapeutics
    Inventors: Neel K. Anand, Franco J. Duarte, Wen Zhang, Zhongxu Ren
  • Multi-arm polymer prodrugs
    Patent number: 9808533
    Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: November 7, 2017
    Assignee: Nektar Therapeutics
    Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
  • Methods for treating humans having brain cancer
    Patent number: 9801873
    Abstract: Among other things, a method of treating a human having brain cancer is, the method comprising administering via a non-continuous dosing regimen to the human having brain cancer, a therapeutically effective amount of a pharmaceutical composition comprising a prodrug or a pharmaceutically acceptable salt thereof, wherein the non-continuous dosing regimen comprises administering the pharmaceutical composition no more frequently than once every seven days for at least two dosings.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: October 31, 2017
    Assignee: Nektar Therapeutics
    Inventors: Michael A. Eldon, Shibani S. Harite, Tamra L. Barker
  • Oligomer-beta blocker conjugates
    Patent number: 9782488
    Abstract: The invention provides water-soluble oligomer-beta blocker drug conjugates. A drug conjugate of the invention can be administered by any of a number of administration routes and exhibits properties that are different from the corresponding beta blocker not attached to the water-soluble oligomer.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: October 10, 2017
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte
  • Composition comprising a polymeric reagent
    Patent number: 9775911
    Abstract: The present invention provides among other things a composition of a polymeric reagent and an antioxidant, such as butylated hydroxyl toluene.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: October 3, 2017
    Assignee: Nektar Therapeutics
    Inventors: Michael D. Bentley, Sean M. Culbertson, Samuel P. McManus
  • Polymer conjugates of protegrin peptides
    Patent number: 9763995
    Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: September 19, 2017
    Assignee: Nektar Therapeutics
    Inventors: Yujun Wang, Haim Moskowitz, Xiaofeng Liu, Steven O. Roczniak, Mary J. Bossard
  • SEALED NEBULIZER LIQUID RESERVOIR SYSTEMS AND METHODS
    Publication number: 20170252523
    Abstract: Methods, systems, and devices are described for sealing a nebulizer's liquid reservoir. A nebulizer liquid reservoir may be provided that is in fluid communication with an aerosol generator. The nebulizer liquid reservoir may have an open end and a headspace. A cap may be placed on the open end of the nebulizer liquid reservoir, wherein the cap partially fills the headspace of the nebulizer liquid reservoir. The cap can include a plunger that passes through the cap and allows for air to escape from the headspace of the nebulizer liquid reservoir through the cap. The cap can seal the nebulizer liquid reservoir by actuating the plunger to a locked position. The plunger may create an airtight seal with the cap when in the locked position. An ambient pressure may be maintained in the sealed nebulizer liquid reservoir until a portion of the liquid is dispensed.
    Type: Application
    Filed: May 18, 2017
    Publication date: September 7, 2017
    Applicant: Nektar Therapeutics
    Inventors: David Blakey, Richard Day
  • Methods for preparing polymeric reagents and compositions of polymeric reagents
    Patent number: 9732189
    Abstract: Methods for preparing active carbonate esters of water-soluble polymers are provided. Also provided are other methods related to the active carbonate esters of water-soluble polymers, as well as corresponding compositions.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: August 15, 2017
    Assignee: Nektar Therapeutics
    Inventors: Antoni Kozlowski, Jon McKannan, Samuel P. McManus
  • Oligomer-tricyclic conjugates
    Patent number: 9725431
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: August 8, 2017
    Assignee: Nektar Therapeutics
    Inventors: Wen Zhang, Xuyuan Gu, Stephanie Allums-Donald, Jennifer Riggs-Sauthier
  • Particulate materials
    Patent number: 9700529
    Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: July 11, 2017
    Assignee: Nektar Therapeutics
    Inventors: Peter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
  • Opioid agonists and uses thereof
    Patent number: 9688638
    Abstract: Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
    Type: Grant
    Filed: November 27, 2014
    Date of Patent: June 27, 2017
    Assignee: Nektar Therapeutics
    Inventors: Franco J. Duarte, Neel K. Anand, Pankaj Sharma, Devendrapratap Singh
  • Negatively biased sealed nebulizer systems and methods
    Patent number: 9682201
    Abstract: Methods, systems, and devices are described for creating a negative bias pressure within a liquid reservoir. Embodiments may include providing a liquid reservoir coupled with an aerosol generator. The liquid reservoir may be sealed to create the sealed reservoir. An ambient pressure may be maintained while the liquid reservoir is being sealed and the ambient pressure may be maintained in the sealed liquid reservoir until a portion of the liquid is dispensed. Further, embodiments may include vibrating the aperture plate to dispense the portion of the liquid. The portion of the liquid dispensed may decreases the amount of the liquid in the sealed reservoir. By decreasing the amount of liquid in the sealed reservoir, a negative bias pressure between an air side and a liquid side of the aperture plate may be created.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: June 20, 2017
    Assignee: Nektar Therapeutics
    Inventors: David Mark Blakey, Richard Francis Day
  • Solid salt form of ?-6-mPEG-O-hydroxycodone as opioid agonists and uses thereof
    Patent number: 9682988
    Abstract: Solid forms of certain opioid agonists are provided herein. Methods of preparing the solid forms, methods of using the solid forms, and pharmaceutical compositions comprising the solid forms are also provided herein.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: June 20, 2017
    Assignee: Nektar Therapeutics
    Inventors: Patricia Andres, Yogesh Datar, Ramakrishna Gadiraju, Bruce Andrew Kowalczyk, Gabriel Christian Kuklis, Mahmoud Mirmehrabi, Nicholas Paschalides